Skip to main content
. 2021 Jun 11;27(16):4599–4609. doi: 10.1158/1078-0432.CCR-21-0205

Table 2.

Descriptive statistics by UROMOL signature classification.

1/Luminal 2/Luminal CIS-like 3/Early basal-like
n = 26 n = 28 n = 24 P
Institution/cohort 0.08
 UNC 7 (26.9%) 8 (28.6%) 13 (54.2%)
 MSK 19 (73.1%) 20 (71.4%) 11 (45.8%)
Age (years) 61.6 (14.9) 65.3 (11.2) 68.3 (10.3) 0.159
Male sex 20 (76.9%) 20 (71.4%) 19 (79.2%) 0.797
Stage 0.001
 T1 4 (15.4%) 15 (53.6%) 16 (66.7%)
 Ta 22 (84.6%) 13 (46.4%) 8 (33.3%)
Gradea <0.001
 High 12 (46.2%) 27 (96.4%) 21 (87.5%)
 Low 14 (53.8%) 0 (0.00%) 2 (8.33%)
Carcinoma in situ 8 (30.8%) 2 (7.14%) 7 (29.2%) 0.063
Tumor cellularitya 0.004
 0–40 6 (23.1%) 11 (40.7%) 16 (69.6%)
 50–90 20 (76.9%) 16 (59.3%) 7 (30.4%)

Note: Data are presented as mean (SD) or n (%).

Abbreviations: CIS, carcinoma in situ; MSK, Memorial Sloan Kettering Cancer Center; SD, standard deviation; UNC, University of North Carolina.

aMissing values omitted.